Entrada Therapeutics
Entrada Therapeutics' revenue fell 87.9% to $25 million in fiscal 2025. Its operating margin was −621.1%, down from 22.3% a year earlier. Free cash flow was −$130 million. The diluted share count rose 6.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Entrada Therapeutics lost money in fiscal 2025: a net loss of $144 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 291 | 189 | 352 | 420 | 296 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 44.5x | 9.6x | 2.3x | 11.2x | 12.5x |
| Quick ratio | 44.5x | 9.6x | 2.3x | 11.2x | 12.5x |
Cash flow
Projections
Project Entrada Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $291,124 of Entrada Therapeutics shares on the open market, and 9 insiders sold $6.7 million, $1.3 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Mpm Bioventures 2018 (b) L.p.10% owner | Sold | 28,837 | $7.13 | $205,608 | Form 4 |
| Sep 8, 2026 | Mpm Bioventures 2018 (b) L.p.10% owner | Sold | 192,500 | $7.41 | $1.4 million | Form 4 |
| Sep 4, 2026 | Mpm Bioventures 2018 (b) L.p.10% owner | Sold | 38,500 | $7.11 | $273,735 | Form 4 |
| Sep 3, 2026 | MPM BioVentures 2014 GP LLC10% owner | Sold | 32,263 | $7.17 | $231,326 | Form 4 |
| Sep 2, 2026 | MPM BioVentures 2014 GP LLC10% owner | Sold | 25,131 | $7.19 | $180,692 | Form 4 |
| Sep 1, 2026 | MPM BioVentures 2014 GP LLC10% owner | Sold | 29,088 | $7.06 | $205,361 | Form 4 |
| Aug 31, 2026 | MPM BioVentures 2014 (B) L.P.10% owner | Sold | 44,259 | $6.99 | $309,370 | Form 4 |
| Aug 28, 2026 | MPM BioVentures 2014 (B) L.P.10% owner | Sold | 3,733 | $7.01 | $26,168 | Form 4 |
| Aug 27, 2026 | MPM BioVentures 2014 (B) L.P.10% owner | Sold | 38,922 | $7.20 | $280,238 | Form 4 |
| Aug 26, 2026 | MPM BioVentures 2018 LLC10% owner | Sold | 14,569 | $7.06 | $102,857 | Form 4 |
| Aug 25, 2026 | MPM BioVentures 2018 LLC10% owner | Sold | 26,522 | $7.54 | $199,976 | Form 4 |
| Aug 24, 2026 | MPM BioVentures 2018 LLC10% owner | Sold | 21,623 | $7.34 | $158,713 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | 42.2% | −597.6% |
| Altman Z'' | 2.67 | 9.40 | 4.24 |
| Accruals ratio | −40.6% | 21.5% | −3.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Fail | Fail |
| F-score | — | — | — |
Compare
Put Entrada Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Entrada Therapeutics | FY25 | −87.9% | −621.1% | −509.6% | — | — | — | |
| Metagenomi Therapeutics | FY25 | −51.8% | −380.9% | −354.9% | — | — | — | Compare |
| Alector | FY25 | −79.1% | −741.3% | −874.7% | — | — | 1 | Compare |
| LENZ Therapeutics | FY25 | — | −477.5% | −366.7% | — | — | — | Compare |
| Precision Biosciences | FY25 | −50.1% | −152.2% | −192.4% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | 129 | 211 | 25 |
| Revenue growth | — | — | — | — | 63.4% | −87.9% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 21 | 36 | 67 | 100 | 125 | 142 |
| Operating income | −27 | −51 | −97 | −3 | 47 | −158 |
| Net income | −26 | −51 | −95 | −7 | 66 | −144 |
| Diluted EPS (US$) | −24.00 | −8.16 | −3.02 | −0.20 | 1.68 | −3.47 |
| Diluted shares (millions) | 1 | 6 | 31 | 33 | 39 | 41 |
| Cash flow | ||||||
| Cash from operations | −26 | −51 | −94 | 140 | −42 | −128 |
| Capital expenditure | 2 | 5 | 3 | 6 | 3 | 1 |
| Free cash flow | −28 | −55 | −97 | 134 | −45 | −130 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 2 | 10 | 13 | 18 | 20 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 39 | 291 | 189 | 352 | 420 | 296 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 44 | 306 | 252 | 469 | 526 | 377 |
| Total liabilities | 3 | 7 | 40 | 227 | 98 | 71 |
| Shareholders' equity | −42 | 299 | 213 | 242 | 429 | 306 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | −2.5% | 22.3% | −621.1% |
| Net margin | — | — | — | −5.2% | 31.1% | −565.5% |
| Free cash flow margin | — | — | — | 104.0% | −21.2% | −509.6% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | 42.2% | −597.6% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −39.8% | −37.0% | −2.9% | 19.6% | −39.1% |
| Return on assets | — | −29.3% | −33.9% | −1.9% | 13.2% | −31.8% |
| Net debt to EBITDA | — | — | — | — | — | — |